⌕
Praxis Precision Medicines · PRAX · Nasdaq
Tenet 45 · Mixed
Compare
$310.27−5.44%At closeTenet 45 · Mixed
$310.27−17.86 (−5.44%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Praxis Precision Medicines (PRAX) Stock

Praxis Precision Medicines (PRAX) closed at $310.27 on Nov 16, 2026; its Tenet Score is 45 of 100 against 313 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

32 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$310.27
Nov 16, 2026
Market cap
$9.2B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
160.11 – 392.70
low → high · as of close, Nov 13, 2026
Tenet Score
45/100
Mixed · 313 Healthcare peers

Industry: Drugs

Praxis Precision Medicines Inc scores 45/100. Mixed. Strongest on financial health, quality is the soft spot versus 313 Healthcare peers. Insufficient inputs: Tenet 45 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=313
45/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
28
Quality
17
Health
90
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueFQualityFHealthAGrowth—MomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
7.3×
price to book value
P/S
—
no P/S on file
ROE
−45%
return on equity
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
14.53
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Praxis Precision Medicines Inc

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA recept…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=313) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 88 US ETFs · top wrappers by weightSee all ETFs holding PRAX →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Praxis Precision Medicines in?

Praxis Precision Medicines is in the Healthcare sector and the Drugs industry.

What is Praxis Precision Medicines' Tenet Score?

Praxis Precision Medicines' Tenet Score is 45 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.